BSH 2024 Programme - UKMRA / UKMS Session: Prognostic risk factors and Bispecific Antibodies for Multiple Myeloma

UKMRA / UKMS Session: Prognostic risk factors and Bispecific Antibodies for Multiple Myeloma - how to bring them into practice

Tracks

Track 3

Tuesday, April 30, 2024

2:15 PM - 3:45 PM

Room 3A

Details

Prognostic tests and treatments for multiple myeloma are rapidly evolving with technological advances. This session addresses the real world challenge of how best to integrate such advances into practice. Dr Martin Kaiser, Consultant Haematologist at the Royal Marsden Hospital will provide an update to prognostic factors used for myeloma with an overview of cytogenetic risk stratification and the use of diagnostic platforms such as gene expression profiling as well as other biomarkers. Prof Saad Usmani, Chief of Myeloma Service at MSKCC, New York and Chair of the US Alliance co-operative group will describe how he uses bispecific T cell engagers in routine practice, how to manage the toxicity profile and where the future lies. Dr Frances Seymour, Consultant Haematologist at Leeds Teaching Hospitals will describe how T cell immunotherapies can be implemented in the UK drawing on learnings from other haematological cancers. There will then be a discussion chaired by Dr Rakesh Popat, Consultant Haematologist at University College London and Dr Ceri Bygrave, Consultant Haematologist at University Hospital of Wales on how we an incorporate these new developments into routine UK practice to improve outcomes for our patients.